NOS2 and pulmonary arterial hypertension: Despite many promising results from preclinical studies, further attempts are needed to achieve the evaluation of iNOS-targeting drug candidates, overcoming the limitations discussed in Section 9, and the eventual optimization of current treatment strategies for pulmonary hypertension.